Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Paul Feuerstadt, MD, FACG, AGAF

Assistant Clinical Professor of Medicine
Yale University School of Medicine
Attending Gastroenterologist
PACT Gastroenterology Center
New Haven, Connecticut

Disclosures

Paul Feuerstadt, MD, FACG, AGAF, has the following relevant financial relationships:
Consultant or advisor for: Ferring Pharmaceuticals; Merck and Co.; Seres Therapeutics; Takeda Pharmaceuticals
Speaker or member of speakers bureau for: Ferring Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals
Research funding from: Adare Pharmaceuticals; Da Volterra Pharmaceuticals; Ferring Pharmaceuticals; Finch Therapeutics; Seres Therapeutics

Sahil Khanna, MBBS, MS

Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota

Disclosures

Sahil Khanna, MBBS, MS, has the following relevant financial relationships:
Research funding from: Ferring Pharmaceuticals; Finch Pharmaceuticals; Pfizer; Rebiotix; Seres Therapeutics; Vedanta
Ownership interest: Jetson Probiotics
Other: Consulting – Niche; DSMB – Takeda; Consulting – ProBiotech; Immuron

Caterina Oneto, MD

Clinical Instructor, Department of Medicine
NYU Grossman School of Medicine
Gastroenterologist
NYU Langone Hospitals
New York, New York

Disclosures

Caterina Oneto, MD, has the following relevant financial relationships:
Speaker or member of speakers bureau for: AbbVie; Bristol Myers Squibb; Salix
Research funding from: Salix
Contracted researcher for: AbbVie; Rebiotix; Seres Therapeutics

Editor

Roderick Smith, MS

Senior Medical Education Director, Medscape, LLC

Disclosures

Roderick Smith, MS, has no relevant financial relationships.

Compliance Reviewer

Susan L. Smith, MN, PhD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Susan L. Smith, MN, PhD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC

The Microbiome and Recurrent Clostridioides difficile: Trust Your Gut

Authors: Paul Feuerstadt, MD, FACG, AGAF; Sahil Khanna, MBBS, MS; Caterina Oneto, MD
CME / ABIM MOC Released: 6/7/2022
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/7/2023, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for gastroenterologists, infectious disease specialists, and primary care physicians.

The goal of this activity is that learners will be better able to provide expert perspective and guidance on the evolving understanding of the microbiome, gut dysbiosis, and current and emerging treatments for recurrent CDI, with appropriate incorporation of new therapies into patient care.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Mechanism of action of microbiome-directed therapeutics for CDI
Have greater competence related to
- Determining a patient care strategy for recurrent CDI
Demonstrate greater confidence in their ability to
- Discuss the different attributes of microbiome-based therapies

Disclosures

Faculty

Paul Feuerstadt, MD, FACG, AGAF

Assistant Clinical Professor of Medicine
Yale University School of Medicine
Attending Gastroenterologist
PACT Gastroenterology Center
New Haven, Connecticut

Disclosures

Paul Feuerstadt, MD, FACG, AGAF, has the following relevant financial relationships:
Consultant or advisor for: Ferring Pharmaceuticals; Merck and Co.; Seres Therapeutics; Takeda Pharmaceuticals
Speaker or member of speakers bureau for: Ferring Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals
Research funding from: Adare Pharmaceuticals; Da Volterra Pharmaceuticals; Ferring Pharmaceuticals; Finch Therapeutics; Seres Therapeutics

Sahil Khanna, MBBS, MS

Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota

Disclosures

Sahil Khanna, MBBS, MS, has the following relevant financial relationships:
Research funding from: Ferring Pharmaceuticals; Finch Pharmaceuticals; Pfizer; Rebiotix; Seres Therapeutics; Vedanta
Ownership interest: Jetson Probiotics
Other: Consulting – Niche; DSMB – Takeda; Consulting – ProBiotech; Immuron

Caterina Oneto, MD

Clinical Instructor, Department of Medicine
NYU Grossman School of Medicine
Gastroenterologist
NYU Langone Hospitals
New York, New York

Disclosures

Caterina Oneto, MD, has the following relevant financial relationships:
Speaker or member of speakers bureau for: AbbVie; Bristol Myers Squibb; Salix
Research funding from: Salix
Contracted researcher for: AbbVie; Rebiotix; Seres Therapeutics

Editor

Roderick Smith, MS

Senior Medical Education Director, Medscape, LLC

Disclosures

Roderick Smith, MS, has no relevant financial relationships.

Compliance Reviewer

Susan L. Smith, MN, PhD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Susan L. Smith, MN, PhD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Infectious Diseases

CME / ABIM MOC

The Microbiome and Recurrent Clostridioides difficile: Trust Your Gut

Authors: Paul Feuerstadt, MD, FACG, AGAF; Sahil Khanna, MBBS, MS; Caterina Oneto, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 6/7/2022

Valid for credit through: 6/7/2023, 11:59 PM EST

processing....

Assessment Survey

Before you begin, please take this brief survey.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Paul Feuerstadt, MD, FACG, AGAF

Sahil Khanna, MBBS, MS

Caterina Oneto, MD

Editor

Roderick Smith, MS

Compliance Reviewer

Susan L. Smith, MN, PhD

Peer Reviewer

CME / ABIM MOC

The Microbiome and Recurrent Clostridioides difficile: Trust Your Gut

Target Audience and Goal Statement

Disclosures

Faculty

Paul Feuerstadt, MD, FACG, AGAF

Sahil Khanna, MBBS, MS

Caterina Oneto, MD

Editor

Roderick Smith, MS

Compliance Reviewer

Susan L. Smith, MN, PhD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The Microbiome and Recurrent Clostridioides difficile: Trust Your Gut

Assessment Survey